It has been reported that theophylline is primarily metabolized via hepatic CYP1A1/2, 2B1/2, and 3A1/2, and 1,3-dimethyluric acid (1,3-DMU) is primarily formed via CYP1A1/2 in rats. Compared with control rats, the expression of CYP1A subfamily, 2B1/2, and 3A subfamily significantly decreased 24 h (24-h KPLPS rats) after intravenous administration of lipopolysaccharide derived from Klebsiella pneumoniae (KPLPS) to rats but returned to that in control rats after 96 h (96-h KPLPS rats). After intravenous or oral administration of theophylline to 24-h KPLPS rats, the values for the total area under the plasma concentration-time curve from time zero to time infinity of theophylline and 1,3-DMU became significantly greater (46.5 and 34.0% increase after intravenous and oral administration, respectively) and smaller (36.3 and 21.6% decrease, respectively), respectively. Because theophylline is a low hepatic extraction ratio drug in rats, the above results could have been due to significantly slower CL int for the disappearance of theophylline and for the formation of 1,3-DMU (37.1 and 60.6% decrease, respectively). However, in 96-h KPLPS rats, the pharmacokinetic parameters of theophylline and 1,3-DMU returned fully or partially to those in control rats. These findings indicate the existence of time-dependent effects of KPLPS on the pharmacokinetics of theophylline and 1,3-DMU in rats.
R&D (Detroit, MI) and Bio-Rad Laboratories (Hercules, CA), respectively. Enhanced chemiluminescence reagents were products from Amersham Biosciences Corporation (Piscataway, NJ). Other chemicals were of reagent or HPLC grade.
Animals. The protocols for the animal studies were approved by the Animal Care and Use Committee of the College of Pharmacy of Seoul National University, Seoul, South Korea. Male Sprague-Dawley rats (6 -8 weeks old and weighing 265-325 g) were purchased from Taconic Farms Inc. (Samtako Bio Korea, O-San, South Korea). The procedures used for maintenance of the rats were similar to a reported method (Kim et al., 1993) .
Administration of KPLPS to Rats. Rats were randomly divided into three groups: 24-h KPLPS, 96-h KPLPS, and control rats. KPLPS (dissolved in 0.9% NaCl-injectable solution) at a dose of 0.5 mg (1 ml)/kg was administered via the tail vein to rats 24 h and 96 h before administration of theophylline. An equal volume of 0.9% NaCl-injectable solution was injected into control rats.
Western Blot Analysis. The procedures used for the preparation of hepatic microsomal fractions of 24-h KPLPS, 96-h KPLPS, and control rats (n ϭ 5, each) were similar to a reported method . The procedures used for Western blot analysis for 24-h KPLPS, 96-h KPLPS, and control rats (n ϭ 3, each) were similar to a reported method (Kim et al., 2001) .
Measurement of V max , K m , and CL int for the Disappearance of Theophylline and for the Formation of 1,3-DMU in Hepatic Microsomal Fractions. The procedures used for the measurement of V max (the maximum velocity) and K m (the apparent Michaelis-Menten constant, the concentration at which the rate is one-half V max ) for the disappearance of theophylline and for the formation of 1,3-DMU were similar to a reported method . The concentrations of theophylline were 0.1, 0.2, 0.5, 1, 2, 5, 7.5, or 10 mM. The reaction was terminated by addition of 0.5 ml of acetonitrile containing 20 g/ml ␤-hydroxyethyltheophylline (internal standard) after 30 min of incubation. The kinetic constants, V max and K m , for the disappearance of theophylline and for the formation of 1,3-DMU were calculated using a nonlinear regression method (Duggleby, 1995) . The intrinsic clearance (CL int ) for the disappearance of theophylline and for the formation of 1,3-DMU was calculated by dividing the V max by the K m .
Disappearance of Theophylline and Formation of 1,3-DMU after Incubation of Theophylline with CYP1A1, 1A2, 2B1, 3A1, and 3A2. The procedures used were similar to those described for the above V max and K m studies. Theophylline (5 mM) was incubated with microsomes from baculovirus-infected insect cells expressing CYP1A1, 1A2, 2B1, 3A1, and 3A2 (final concentration of 60 pmol/ml, each). Acetonitrile, 300 l, was added after 60 min of incubation to terminate enzyme activity.
Intravenous or Oral Administration of Theophylline to Rats. The procedures used, including the pretreatment and cannulation of the jugular vein (for drug administration in the intravenous study) and the carotid artery (for blood sampling), are similar to a reported method (Kim et al., 1993) . Theophylline (aminophylline injectable solution was diluted in 0.9% NaCl-injectable solution) at a dose of 5 mg/kg was administered intravenously over 1 min (total injection volume of approximately 0.6 ml) via the jugular vein to rats in each group (n ϭ 7, 8, and 9 for 24-h KPLPS, 96-h KPLPS, and control rats, respectively). A blood sample (approximately 0.12 ml) was collected via the carotid artery at 0 (control), 1 (the end of the infusion), 5, 15, 30, 45, 60, 90, 120, 180, 240, 300 , and 360 min after the start of the intravenous infusion of theophylline. Blood samples were immediately centrifuged (16,000g, 5 min), and a 50-l aliquot of each plasma sample was stored at Ϫ70°C until used for the HPLC analysis of theophylline and 1,3-DMU (Yang et al., 2008) . The procedures used for the preparation and handling of 24-h urine samples and the entire gastrointestinal tract content samples (including its contents and feces) at 24 h were similar to a reported method (Kim et al., 1993) .
The same dose of theophylline (the same solution used in the intravenous study) was administered orally (total oral volume of approximately 0.6 ml) using a feeding tube to rats in each group (n ϭ 7, 7, and 8 for 24-h KPLPS, 96-h KPLPS, and control rats, respectively). Blood samples were collected via the carotid artery at 0, 5, 15, 30, 45, 60, 90, 120, 180, 240, 360, 480 , and 600 min after oral administration of theophylline. Other procedures were similar to those for the intravenous study.
HPLC Analysis of Theophylline and 1,3-DMU. Concentrations of theophylline and 1,3-DMU in the samples were determined by a slight modification (Yang et al., 2008 ) of a reported HPLC method (Kawakatsu et al., 1989) . The retention times of theophylline, 1,3-DMU, and internal standard in rat plasma samples were approximately 11.1, 6.3, and 13.2 min, respectively, and the corresponding values in rat urine samples were approximately 18.7, 9.9, and 23.5 min, respectively. The quantitation limits of theophylline in rat plasma and urine samples were 0.1 and 1 g/ml, respectively, and the corresponding values of 1,3-DMU were 0.05 and 1 g/ml, respectively.
Pharmacokinetic Analysis. The total area under the plasma concentrationtime curve from time 0 to time infinity (AUC) was calculated using the trapezoidal rule-extrapolation method (Chiou, 1978) . The area from the last datum point to time infinity was estimated by dividing the last measured plasma concentration by the terminal-phase rate constant.
Standard methods (Gibaldi and Perrier, 1982) were used to calculate the following pharmacokinetic parameters using a noncompartmental analysis (WinNonlin; Pharsight Corporation, Mountain View, CA): the time-averaged total body, renal, and nonrenal clearances (CL, CL R , and CL NR , respectively); the terminal half-life; the first moment of AUC; the mean residence time (MRT); the apparent volume of distribution at steady state (V ss ); and the extent of absolute oral bioavailability (F) (Kim et al., 1993) . The peak plasma concentration (C max ) and time to reach C max (T max ) were directly read from the experimental data.
Statistical Analysis. A P value of Ͻ0.05 was deemed statistically significant using a Duncan's multiple range test (SPSS Inc., Chicago, IL) and a posteriori analysis of variance among the three means for the unpaired data. All data are expressed as mean Ϯ S.D., except median (ranges) for T max .
Results and Discussion
Treatment of KPLPS (both in 24-h and 96-h KPLPS rats) caused significant decrease in body weight gain compared with that in control rats (Tables 1 and 2 ). However, the liver and kidney functions in 24-h and 96-h KPLPS rats were not seriously impaired based on the plasma chemistry data and tissue histology (data not shown).
Many investigators reported dose-dependent metabolic disposition of theophylline in humans (Lesko, 1979; Massey et al., 1984) and rats (Teunissen et al., 1985) . Thus, theophylline at a dose of 5 mg/kg, which has been reported to be in the ranges of dose-independent metabolic disposition of theophylline in rats (for up to 10 mg/kg) (Teunissen et al., 1985) , was administered intravenously or orally to rats. The expression of hepatic CYP1A subfamily, 2B1/2, and 3A subfamily in three groups of rats is shown in Fig. 1 . After intravenous and oral administration of theophylline to the three groups of rats, the plasma concentration-time curves of theophylline and 1,3-DMU are shown in Fig. 2 , and the relevant pharmacokinetic parameters are listed in Tables 1 and 2. The contribution of the gastrointestinal (including biliary) excretion of unchanged theophylline to the CL NR of theophylline was almost negligible; theophylline was below the detection limit in the gastrointestinal tract at 24 h (GI 24 h ) for all groups of rats (Table 1) . However, being below the detection limit of GI 24 h was not likely due to chemical and enzymatic degradation of theophylline in rats' gastric juices, because theophylline was stable for up to 24 h of incubation in various buffer solutions that had pHs ranging from 1 to 13 and for up to 4 h of incubation in four rats' gastric juices (pHs of 1.5, 1.5, 2.0, and 2.0, respectively). More than 91.8 and 94.5% of the spiked amounts of theophylline were recovered from various buffer solutions and rats' gastric juices, respectively, using a reported method (Yu et al., 2003) . Kim et al. (2003) reported that the contribution of the biliary excretion of unchanged theophylline to the CL NR of theophylline is almost negligible. Thus, the CL NR of theophylline listed in Table 1 could represent the metabolic clearance of theophylline. Additionally, changes in the CL NR of theophylline could represent changes in the metabolism of theophylline in rats. Yang et al. (2008) reported that theophylline is primarily metabolized via hepatic CYP1A1/2, 2B1/2, and 3A1/2, and 1,3-DMU is primarily formed via CYP1A1/2 in rats. To confirm the P450 Compared with control rats, the expression of hepatic CYP1A subfamily, 2B1/2, and 3A subfamily significantly decreased (77.3, 47.2, and 59.1% decrease, respectively) in 24-h KPLPS rats (Fig. 1) . Thus, it could be expected that, compared with control rats, the CL NR of theophylline would be slower in 24-h KPLPS rats, because theophylline is a low hepatic extraction ratio drug in rats. The hepatic first-pass effect of theophylline in this study was estimated using a reported equation (Lee and Chiou, 1983 ) based on the CL NR of 
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at ASPET Journals on June 26, 2017 dmd.aspetjournals.org theophylline (Table 1 ) and the hepatic blood flow rate of 55.2 ml/ min/kg (Davies and Morris, 1993) and the hematocrit of approximately 45% (Mitruka and Rawnsley, 1981) in rats; the value thus estimated was 4.41% in control rats. Thus, the hepatic clearance of theophylline depends more on the CL int for the disappearance of theophylline rather than on the hepatic blood flow rate ( Shand , 1975) . As expected, after intravenous administration of theophylline to 24-h KPLPS rats, the CL NR of theophylline was significantly slower (41.9% decrease) than that in control rats (Table 1) . The significantly slower CL NR of theophylline in 24-h KPLPS rats could be supported by significantly slower (37.1% decrease) CL int for the disappearance of theophylline (3.42 ϫ 10 Ϫ3 and 2.15 ϫ 10 Ϫ3 ml/min/mg protein for control and 24-h KPLPS rats, respectively) than that in control rats. The significantly slower CL int could have been due to a decreased expression of the hepatic CYP1A subfamily, 2B1/2, and 3A subfamily in 24-h KPLPS rats (Fig. 1) . In 24-h KPLPS rats, the significantly smaller AUC of 1,3-DMU could also be supported by the significantly slower (60.6% decrease) CL int for the formation of 1,3-DMU (0.0625 ϫ 10 Ϫ3 and 0.0246 ϫ 10 Ϫ3 ml/ min/mg protein for control and 24-h KPLPS rats, respectively) than that in control rats. This could have been due to decreased expression of CYP1A compared with that in control rats (Fig. 1) . Microsomal protein contents were 143 Ϯ 16.0, 133 Ϯ 20.3, and 129 Ϯ 16.7 mg/whole liver for 24-h KPLPS, 96-h KPLPS, and control rats, respectively; they were not significantly different among three groups of rats.
After oral administration of theophylline to 24-h KPLPS rats, the AUC values of theophylline and 1,3-DMU were also significantly greater (34.0% increase) and smaller (21.6% decrease), respectively, than that in control rats (Table 2 ). However, this was not likely due to increased gastrointestinal absorption of theophylline compared with that in control rats, because the GI 24 h values were below the detection limit after oral administration of theophylline to all groups of rats (Table 2) . Thus, theophylline is almost completely absorbed from all groups of rats. Haruta et al. (1998) also reported that theophylline is a highly absorbable drug without the first-pass elimination in rats. Changes in the AUC values of theophylline and 1,3-DMU after oral administration of theophylline to 24-h KPLPS rats could have also been due to the same reasons as explained in the intravenous study, since the first-pass effect of theophylline is almost negligible in rats (Haruta et al., 1998) .
In 96-h KPLPS rats, some pharmacokinetic parameters of theophylline and 1,3-DMU are expected to return fully or partially to that in control rats, because the expression of hepatic CYP1A subfamily, 2B1/2, and 3A subfamily (Fig. 1) and the CL int for the disappearance of theophylline (3.42 ϫ 10 Ϫ3 and 3.75 ϫ 10 Ϫ3 ml/min/mg protein for control and 96-h KPLPS rats, respectively) and for the formation of 1,3-DMU (0.0625 ϫ 10 Ϫ3 and 0.0539 ϫ 10 Ϫ3 ml/min/mg protein for control and 96-h KPLPS rats, respectively) returned to those in control rats. As expected, after intravenous or oral administration of theophylline to 96-h KPLPS rats, the AUC, terminal half-life, MRT, CL, CL R , and CL NR of theophylline and AUC of 1,3-DMU returned fully or partially to those in control rats. Wang et al. (1993) reported that the pharmacokinetic parameters of 1-MX, 1,3-DMU, and theophylline are not changed after intravenous administration of theophylline at a dose of 10 mg/kg to male Wistar rats 2 h after 20 to 30 min intravenous infusion of KPLPS at a dose of 0.25 mg/kg. This could have been because the expression of CYP1A subfamily, 2B1/2, and 3A subfamily is not altered 2 h after KPLPS administration to rats.
In conclusion, significant changes in the pharmacokinetic parameters of theophylline and 1,3-DMU were observed in 24-h KPLPS rats, and this could have been due to decreased expression of hepatic CYP1A subfamily, 2B1/2, and 3A subfamily compared with that in control rats. However, no such changes were observed in 96-h KPLPS rats, and this could have been due to return of the expression of hepatic CYP1A subfamily, 2B1/2, and 3A subfamily to that in control rats. These findings indicate the existence of time-dependent effects of KPLPS on the pharmacokinetics and metabolism of theophylline in rats.
